- Endocrine disorders, including diabetes, PCOS, and hormonal deficiencies, are increasingly being addressed with advanced therapeutic and diagnostic solutions due to rising global prevalence, growing health awareness, and technological progress in endocrinology care
- The escalating demand for endocrine disorder treatments is primarily fueled by increasing hormonal imbalances across populations, growing incidence of lifestyle-related conditions such as obesity and diabetes, and the surge in early screening and diagnosis owing to improved healthcare access and patient education
- North America dominated the endocrine disorders market with the largest revenue share of 41.8% in 2024, driven by robust healthcare infrastructure, high awareness levels, and a strong presence of major pharmaceutical companies. The U.S. leads the region, backed by early adoption of hormone therapies, continuous R&D investment, and growing patient preference for personalized medicine
- Asia-Pacific is expected to be the fastest-growing region with 12.4% CAGR in the endocrine disorders market during the forecast period, attributed to increasing urbanization, rising disposable incomes, growing awareness of endocrine health, and expansion of healthcare access in countries such as China and India
- Diabetes segment dominated the endocrine disorders market with a market share of 61.3% in 2024, owing to its high prevalence worldwide, increased screening rates, and strong product pipeline in insulin and non-insulin therapies. The demand is further propelled by innovations in glucose monitoring and digital health integration
